Search
Vir Biotechnology Inc
VIRAdd to Watchlist
8.660USD
-0.240-2.70%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.46BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Vir Biotechnology Inc is 8.60, ranking 97 out of 385 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 31.00 and a low of 12.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
21.556
Target Price
+148.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Vir Biotechnology Inc
VIR
10
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Vir Biotechnology Inc's expected revenue for the next quarter?
Vir Biotechnology Inc's expected revenue is 216.46M.
What is Vir Biotechnology Inc's price target?
Analysts forecast that Vir Biotechnology Inc's price target is USD 15.00, with the highest forecast at USD 31.00 and the lowest forecast at USD 12.00.
How have Vir Biotechnology IncVIR's recent earnings per share performed?
The market expectation was USD -0.85, while Vir Biotechnology IncVIR's earnings per share (EPS) for the previous quarter was USD -0.31. EPS for the next quarter is expected at USD 0.33.
What is the analyst rating for Vir Biotechnology Inc?
Based on the ratings of Vir Biotechnology Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.